Comparison of covid-19 and non-covid-19 pneumonia in down syndrome

Altres ajuts: Jerôme Lejeune Foundation (No 2002, 1777-2018); NIH (1R01EB 028159-01) ; Ministerio de Ciencia e Innovación; Centros de Excelencia Severo Ochoa; CERCA Programme/Generalitat de Catalunya; CIBER of Rare Diseases (CIBERER); CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN); Fondo Europeo de Desarrollo Regional (FEDER); HERCULES Center (NIEHS P30ES019776); LuMind IDSC Foundation.Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID- 19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19